文献速递创面修复瘢痕与激光

人胎盘间充质干细胞外泌体在创面愈合与瘢痕治疗中的系统综述与Meta分析

Human Placental Mesenchymal Stem Cell-Derived Exosomes in Wound Healing and Scar Therapy: A Systematic Review and Meta-analysis.
PubMed 文献 · Aesthet Surg J · 2026-01-01

该研究通过系统综述与Meta分析评估人胎盘间充质干细胞外泌体(hpMSC-exosomes)在创面愈合和瘢痕治疗中的证据,汇总21项临床前研究(323只动物)显示创面愈合率、新生血管密度、再上皮化率和胶原沉积均优于对照,并纳入作者7年738例临床病例系列。人体现有证据主要为早期试验、病例系列和观察性研究,需大规模临床试验推进。

要点

  • hpMSC-exosomes在动物模型中促进创面愈合和改善瘢痕相关参数。
  • 作者7年738例临床经验涵盖175例创面愈合和118例瘢痕治疗。
  • 标准化生产与FDA批准是临床推广的关键前提。

核心结论

  • hpMSC-exosomes是创面愈合与瘢痕治疗有前景的治疗方式,已显示安全性和有效性。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Cochrane Library、EMBASE、Web of Science和ClinicalTrials.gov。
  • Meta分析纳入21项全球临床前研究(323只动物),并纳入作者7年738例临床病例系列。

主要发现

  • Meta分析显示hpMSC-exosomes在创面愈合率、新生血管密度、再上皮化率和胶原沉积方面优于对照。
  • hpMSC-exosomes通过增强血管生成、减轻炎症、改善胶原产生和免疫调节加速创面愈合。
  • 作者系列中175例涉及创面愈合、118例涉及瘢痕治疗。

临床怎么用

  • 现有证据支持hpMSC-exosomes用于创面愈合和瘢痕治疗的研究性应用。
  • 临床推广前需解决标准化生产流程和监管批准问题。

局限性

  • 多数研究使用啮齿动物模型,向人体转化有限。
  • 人体现有证据主要基于早期试验、病例系列和观察性研究。
  • 需大规模、设计良好的临床试验推进外泌体治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Exosome therapy represents an emerging regenerative medicine approach for optimizing wound healing and reducing scarring. Extensive pre-clinical research on human placental mesenchymal stem cell-derived exosomes (hpMSC-exosomes) demonstrates significant therapeutic potential in aesthetic and reconstructive surgery applications. Despite compelling preclinical evidence supporting the efficacy of exosomes in wound healing, human clinical studies remain scarce. The author's current study includes 738 patients treated with hpMSC-exosomes over a 7-year period across multiple aesthetic and reconstructive indications, with 175 cases involving wound healing and 118 cases involving scar therapy. The objective of this systematic review and meta-analysis is to comprehensively evaluate the current evidence for hpMSC-exosomes in wound healing and scar therapy, analyzing their mechanisms of action, clinical applications, and safety profiles through a review of preclinical studies, safety data, and clinical case series in both animals and humans. Analysis of the author's series will be included. Information sources included PubMed, Cochrane Library, EMBASE, Web of Science, and ClinicalTrials.gov resulting in a meta-analysis of 21 global preclinical studies (323 animals) which demonstrated superior outcomes compared with controls across multiple parameters: wound healing rate, neovascular density, re-epithelialization rate, and collagen deposition. hpMSC-exosomes demonstrated accelerated wound healing through enhanced angiogenesis, reduced inflammation, improved collagen production, and immunomodulatory effects. Most studies utilized rodent models, with limited translation to human trials. Current human evidence is predominantly based on early-phase trials, case series, and observational studies. Large-scale, well-designed clinical trials are essential to advancing exosome therapy in wound healing and scar management. hp-MSC-exosomes represent a promising therapeutic modality for wound healing and scar therapy with demonstrated safety and efficacy. Standardization of manufacturing processes and FDA approval remain critical for widespread clinical implementation. Level of Evidence: 3 (Therapeutic).

来源:Aesthet Surg J,查看原文。版权归原作者所有。

引用

  1. Chernoff G. Human Placental Mesenchymal Stem Cell-Derived Exosomes in Wound Healing and Scar Therapy: A Systematic Review and Meta-analysis. Aesthet Surg J. 2026. PMID: 41800724. doi:10.1093/asj/sjaf163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。